SOX2 and breast cancer: As illustrated in Figure 2, ER+ BC patients who were included in the KM survival analysis displayed high expression levels, with NANOG at around 66%, SOX2 at 54%, POU5F1 at 31%, and ALDH1A1 at 44%.